Human

The primary goal of this Human Insulin Market report is to maintain the record of Unusual growth strategies adopted by various companies are creating new standards for competition in the Human Insulin market. Businesses around the world are aiming at increasing their profit margin and establishing a stronghold in the market. The impact of prevailing regulatory scenario on both regional and worldwide Human Insulin market is provided in detail in the report.

Get Sample Copy of Human Insulin Market Report @ https://www.industryresearch.co/enquiry/request-sample/13999756

Key Market Trends: – Growing Obesity and Diabetes Prevalence of Type 2, Especially in Developing Countries

The exact cause of Type 1 diabetes is unknown, but Type 2 diabetes is caused by lifestyle changes happening daily. The prevalence rate of Type 2 diabetes has quadrupled, when compared to 40 years ago. Although oral drugs are considered as a standard care treatment for Type 2 patients, there has been a rise in the need for using insulin, along with the conventional medication, in order to help stabilize blood glucose levels. This trend has attracted many players, both local and international, to enter into the biosimilar market.
The prevalence of Type 2 diabetes mellitus (T2DM) has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and the primary risk factor for T2DM. Diabetes ranks among the fast-growing chronic diseases in the United States.
India is among the top three countries with a high incidence of diabetes. Many reports and surveys have documented a drastic increase in the diabetic population based on lifestyle habits. Significant urbanization has enabled physical inactivity and diabetes is a major health concern.
The R&D in the insulin segments are rising year-on-year, as researchers are trying to bring out the best molecule for patients’ use, curbing out maximum side effects and increasing their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment considerable demand for insulin, which may drive the market for insulin therapeutics.

North America Dominates the Market

North America dominates the human insulin market, especially the United States, owing to the high prevalence of diabetes in the region, because of a sedentary lifestyle and launch of new drugs in the region.
The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself.
Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of obesity and rising awareness regarding diabetes care in the region.

Human Insulin Market Covers Key Players:

  • Novo Nordisk AS
  • Sanofi Aventis
  • Eli Lilly
  • Biocon
  • Pfizer
  • Julphar
  • Exir
  • Sedico
  • Wockhardt

    Ask for Discount at https://www.industryresearch.co/enquiry/request-discount/13999756

    Geographical Landscape:

    This Report Focuses on the Human Insulin in the market, especially in North America, China, Europe, Japan, Southeast Asia, India. This report categorizes the market based on manufacturers, regions, type, and application

    Market Overview:

  • The human insulin market is expected to register a CAGR of 4.93% during the forecast period of 2019 – 2024 and is estimated to reach USD 25.7 billion by 2019.
  • Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population around the world.
  • Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes.
  • Although insulin has been used in the treatment of diabetes for over 90 years, ly, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, which focuses on managing blood sugar levels, along with insulin, diet, and lifestyle, in order to prevent complications.

    Report Highlights:

    – The report provides a detailed analysis on current and future market trends to identify the investment opportunities

    – Market forecasts till 2024, using estimated market values as the base numbers

    – Key market trends across the business segments, Regions and Countries

    – Key developments and strategies observed in the market

    – Market Dynamics such as Drivers, Restraints, Opportunities and other trends

    – In-depth company profiles of key players and upcoming prominent players

    – Growth prospects among the emerging nations through 2024

    – Human Insulin Market opportunities and recommendations for new investments

    Price Of Report: $ 5000 (SUL)

    Purchase Human Insulin Market Report @ https://www.industryresearch.co/purchase/13999756

    Detailed TOC of Human Insulin Market Research Report 2019 – 2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Product Type
    5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2024)
    5.1.1.1 Lantus
    5.1.1.2 Levemir
    5.1.1.3 Toujeo
    5.1.1.4 Tresiba
    5.1.1.5 Basaglar
    5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2024)
    5.1.2.1 NovoRapid/Novolog
    5.1.2.2 Humalog
    5.1.2.3 Apidra
    5.1.3 Traditional Human Insulins (Value and Volume, 2012-2024)
    5.1.3.1 Novolin/Actrapid/Insulatard
    5.1.3.2 Humulin
    5.1.3.3 Insuman
    5.1.4 Combination Insulins (Value and Volume, 2012-2024)
    5.1.4.1 NovoMix
    5.1.4.2 Ryzodeg
    5.1.4.3 Xultophy
    5.1.5 Biosimilar Insulins (Value and Volume, 2012-2024)
    5.1.5.1 Insulin Glargine Biosimilars
    5.1.5.2 Human Insulin Biosimilars
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume, 2012-2024)
    5.2.1.1.1 Basal or Long-acting Insulins
    5.2.1.1.2 Bolus or Fast-acting Insulins
    5.2.1.1.3 Traditional Human Insulins
    5.2.1.1.4 Combination Insulins
    5.2.1.1.5 Biosimilar Insulins
    5.2.1.2 Canada (Value and Volume, 2012-2024)
    5.2.1.2.1 Basal or Long-acting Insulins
    5.2.1.2.2 Bolus or Fast-acting Insulins
    5.2.1.2.3 Traditional Human Insulins
    5.2.1.2.4 Combination Insulins
    5.2.1.2.5 Biosimilar Insulins
    5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
    5.2.1.3.1 Basal or Long-acting Insulins
    5.2.1.3.2 Bolus or Fast-acting Insulins
    5.2.1.3.3 Traditional Human Insulins
    5.2.1.3.4 Combination Insulins
    5.2.1.3.5 Biosimilar Insulins
    5.2.2 Europe
    5.2.2.1 France (Value and Volume, 2012-2024)
    5.2.2.1.1 Basal or Long-acting Insulins
    5.2.2.1.2 Bolus or Fast-acting Insulins
    5.2.2.1.3 Traditional Human Insulins
    5.2.2.1.4 Combination Insulins
    5.2.2.1.5 Biosimilar Insulins
    5.2.2.2 Germany (Value and Volume, 2012-2024)
    5.2.2.2.1 Basal or Long-acting Insulins
    5.2.2.2.2 Bolus or Fast-acting Insulins
    5.2.2.2.3 Traditional Human Insulins
    5.2.2.2.4 Combination Insulins
    5.2.2.2.5 Biosimilar Insulins
    5.2.2.3 Italy (Value and Volume, 2012-2024)
    5.2.2.3.1 Basal or Long-acting Insulins
    5.2.2.3.2 Bolus or Fast-acting Insulins
    5.2.2.3.3 Traditional Human Insulins
    5.2.2.3.4 Combination Insulins
    5.2.2.3.5 Biosimilar Insulins
    5.2.2.4 Spain (Value and Volume, 2012-2024)
    5.2.2.4.1 Basal or Long-acting Insulins
    5.2.2.4.2 Bolus or Fast-acting Insulins
    5.2.2.4.3 Traditional Human Insulins
    5.2.2.4.4 Combination Insulins
    5.2.2.4.5 Biosimilar Insulins
    5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
    5.2.2.5.1 Basal or Long-acting Insulins
    5.2.2.5.2 Bolus or Fast-acting Insulins
    5.2.2.5.3 Traditional Human Insulins
    5.2.2.5.4 Combination Insulins
    5.2.2.5.5 Biosimilar Insulins
    5.2.2.6 Russia (Value and Volume, 2012-2024)
    5.2.2.6.1 Basal or Long-acting Insulins
    5.2.2.6.2 Bolus or Fast-acting Insulins
    5.2.2.6.3 Traditional Human Insulins
    5.2.2.6.4 Combination Insulins
    5.2.2.6.5 Biosimilar Insulins
    5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
    5.2.2.7.1 Basal or Long-acting Insulins
    5.2.2.7.2 Bolus or Fast-acting Insulins
    5.2.2.7.3 Traditional Human Insulins
    5.2.2.7.4 Combination Insulins
    5.2.2.7.5 Biosimilar Insulins
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume, 2012-2024)
    5.2.3.1.1 Basal or Long-acting Insulins
    5.2.3.1.2 Bolus or Fast-acting Insulins
    5.2.3.1.3 Traditional Human Insulins
    5.2.3.1.4 Combination Insulins
    5.2.3.1.5 Biosimilar Insulins
    5.2.3.2 Brazil (Value and Volume, 2012-2024)
    5.2.3.2.1 Basal or Long-acting Insulins
    5.2.3.2.2 Bolus or Fast-acting Insulins
    5.2.3.2.3 Traditional Human Insulins
    5.2.3.2.4 Combination Insulins
    5.2.3.2.5 Biosimilar Insulins
    5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
    5.2.3.3.1 Basal or Long-acting Insulins
    5.2.3.3.2 Bolus or Fast-acting Insulins
    5.2.3.3.3 Traditional Human Insulins
    5.2.3.3.4 Combination Insulins
    5.2.3.3.5 Biosimilar Insulins
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume, 2012-2024)
    5.2.4.1.1 Basal or Long-acting Insulins
    5.2.4.1.2 Bolus or Fast-acting Insulins
    5.2.4.1.3 Traditional Human Insulins
    5.2.4.1.4 Combination Insulins
    5.2.4.1.5 Biosimilar Insulins
    5.2.4.2 South Korea (Value and Volume, 2012-2024)
    5.2.4.2.1 Basal or Long-acting Insulins
    5.2.4.2.2 Bolus or Fast-acting Insulins
    5.2.4.2.3 Traditional Human Insulins
    5.2.4.2.4 Combination Insulins
    5.2.4.2.5 Biosimilar Insulins
    5.2.4.3 China (Value and Volume, 2012-2024)
    5.2.4.3.1 Basal or Long-acting Insulins
    5.2.4.3.2 Bolus or Fast-acting Insulins
    5.2.4.3.3 Traditional Human Insulins
    5.2.4.3.4 Combination Insulins
    5.2.4.3.5 Biosimilar Insulins
    5.2.4.4 India (Value and Volume, 2012-2024)
    5.2.4.4.1 Basal or Long-acting Insulins
    5.2.4.4.2 Bolus or Fast-acting Insulins
    5.2.4.4.3 Traditional Human Insulins
    5.2.4.4.4 Combination Insulins
    5.2.4.4.5 Biosimilar Insulins
    5.2.4.5 Australia (Value and Volume, 2012-2024)
    5.2.4.5.1 Basal or Long-acting Insulins
    5.2.4.5.2 Bolus or Fast-acting Insulins
    5.2.4.5.3 Traditional Human Insulins
    5.2.4.5.4 Combination Insulins
    5.2.4.5.5 Biosimilar Insulins
    5.2.4.6 Vietnam (Value and Volume, 2012-2024)
    5.2.4.6.1 Basal or Long-acting Insulins
    5.2.4.6.2 Bolus or Fast-acting Insulins
    5.2.4.6.3 Traditional Human Insulins
    5.2.4.6.4 Combination Insulins
    5.2.4.6.5 Biosimilar Insulins
    5.2.4.7 Malaysia (Value and Volume, 2012-2024)
    5.2.4.7.1 Basal or Long-acting Insulins
    5.2.4.7.2 Bolus or Fast-acting Insulins
    5.2.4.7.3 Traditional Human Insulins
    5.2.4.7.4 Combination Insulins
    5.2.4.7.5 Biosimilar Insulins
    5.2.4.8 Indonesia (Value and Volume, 2012-2024)
    5.2.4.8.1 Basal or Long-acting Insulins
    5.2.4.8.2 Bolus or Fast-acting Insulins
    5.2.4.8.3 Traditional Human Insulins
    5.2.4.8.4 Combination Insulins
    5.2.4.8.5 Biosimilar Insulins
    5.2.4.9 Philippines (Value and Volume, 2012-2024)
    5.2.4.9.1 Basal or Long-acting Insulins
    5.2.4.9.2 Bolus or Fast-acting Insulins
    5.2.4.9.3 Traditional Human Insulins
    5.2.4.9.4 Combination Insulins
    5.2.4.9.5 Biosimilar Insulins
    5.2.4.10 Thailand (Value and Volume, 2012-2024)
    5.2.4.10.1 Basal or Long-acting Insulins
    5.2.4.10.2 Bolus or Fast-acting Insulins
    5.2.4.10.3 Traditional Human Insulins
    5.2.4.10.4 Combination Insulins
    5.2.4.10.5 Biosimilar Insulins
    5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
    5.2.4.11.1 Basal or Long-acting Insulins
    5.2.4.11.2 Bolus or Fast-acting Insulins
    5.2.4.11.3 Traditional Human Insulins
    5.2.4.11.4 Combination Insulins
    5.2.4.11.5 Biosimilar Insulins
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
    5.2.5.1.1 Basal or Long-acting Insulins
    5.2.5.1.2 Bolus or Fast-acting Insulins
    5.2.5.1.3 Traditional Human Insulins
    5.2.5.1.4 Combination Insulins
    5.2.5.1.5 Biosimilar Insulins
    5.2.5.2 Iran (Value and Volume, 2012-2024)
    5.2.5.2.1 Basal or Long-acting Insulins
    5.2.5.2.2 Bolus or Fast-acting Insulins
    5.2.5.2.3 Traditional Human Insulins
    5.2.5.2.4 Combination Insulins
    5.2.5.2.5 Biosimilar Insulins
    5.2.5.3 Egypt (Value and Volume, 2012-2024)
    5.2.5.3.1 Basal or Long-acting Insulins
    5.2.5.3.2 Bolus or Fast-acting Insulins
    5.2.5.3.3 Traditional Human Insulins
    5.2.5.3.4 Combination Insulins
    5.2.5.3.5 Biosimilar Insulins
    5.2.5.4 Oman (Value and Volume, 2012-2024)
    5.2.5.4.1 Basal or Long-acting Insulins
    5.2.5.4.2 Bolus or Fast-acting Insulins
    5.2.5.4.3 Traditional Human Insulins
    5.2.5.4.4 Combination Insulins
    5.2.5.4.5 Biosimilar Insulins
    5.2.5.5 South Africa (Value and Volume, 2012-2024)
    5.2.5.5.1 Basal or Long-acting Insulins
    5.2.5.5.2 Bolus or Fast-acting Insulins
    5.2.5.5.3 Traditional Human Insulins
    5.2.5.5.4 Combination Insulins
    5.2.5.5.5 Biosimilar Insulins
    5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
    5.2.5.6.1 Basal or Long-acting Insulins
    5.2.5.6.2 Bolus or Fast-acting Insulins
    5.2.5.6.3 Traditional Human Insulins
    5.2.5.6.4 Combination Insulins
    5.2.5.6.5 Biosimilar Insulins

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk AS
    7.1.2 Sanofi Aventis
    7.1.3 Eli Lilly
    7.1.4 Biocon
    7.1.5 Pfizer
    7.1.6 Julphar
    7.1.7 Exir
    7.1.8 Sedico
    7.1.9 Wockhardt
    7.2 COMPANY SHARE ANALYSIS
    7.2.1 Novo Nordisk AS
    7.2.2 Sanofi Aventis
    7.2.3 Eli Lilly
    7.2.4 Other Companies

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

    About Industry Research:

    Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

    Contact Us:

    Name: Ajay More

    Organization: Industry Research

    Phone: +44 20 3239 8187 / +14242530807

    Email: [email protected]

    Our latest Report: Influenza Diagnostics Market 2019 Industry Key Strategies, Historical Analysis, Segmentation, Application, Technology, Trends and Opportunities Forecasts to 2024

    Our latest Report: Phosphine Market Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Revenue Market Forecast 2023

  • Charles Bevers
    News Reporter